VEGFA and Polypoidal choroidal vasculopathy: Later, with the introduction of anti-VEGF agents, the use of PDT was dramatically reduced, being reserved for specific situations, including as an adjunct therapy with other anti-VEGF agents, such as the FOCUS and the ANCHOR study, in patients with a contraindication to the use of intravitreal anti-VEGF agents, and in patients with conditions as polypoidal choroidal vasculopathy (PCV) in which PDT offered promising results.